While there have been considerable advances in psoriatic arthritis (PsA) treatment, racial and ethnic disparities in clinical outcomes may still exist. A retrospective study using the IBM Explorys platform analyzed the data of 28,360 patients with PsA who had at least two visits with a rheumatologist between 1999 and 2019. Data were stratified by race, sex, laboratory data, clinical characteristics, medication use, and comorbidities. Hypertension, diabetes, obesity, and gout were found to have a greater prevalence in African American patients, while Caucasian patients had a greater likelihood of cancer, anxiety, and osteoporosis. Approximately 80% of Caucasians and 78% of African Americans used NSAIDs (p < 0.009), 51% and 41% used TNFs, and 72% and 98% used DMARDs (p < 0.0001). From findings in a large US real-world database, the researchers concluded that particular comorbidities were found to be more common in African American patients with PsA, warranting greater risk stratification.
Reference: Ross Y, Jaleel S, Magrey M. Racial disparities in comorbidities of patients with psoriatic arthritis [published online ahead of print, 2023 Apr 5]. Rheumatol Int. 2023;10.1007/s00296-023-05322-5. doi:10.1007/s00296-023-05322-5
Link: https://link.springer.com/article/10.1007/s00296-023-05322-5
